Key result
Anysis-200 shows high agreement with VerifyNow for assessing aspirin responsiveness, yielding ~92% sensitivity.
Why the study?
Analysis of responsiveness to antiplatelet therapy is crucial in cardiovascular disease management, prompting evaluation of the new Anysis-200 platelet function analyzer compared with VerifyNow.
Does the Anysis-200 system provide comparable accuracy to VerifyNow in assessing platelet aggregation and aspirin responsiveness in cardiology patients?
Observational (n=85)
Does the Anysis-200 system provide comparable accuracy to VerifyNow in assessing platelet aggregation and aspirin responsiveness in cardiology patients?
Effect estimate: AUC 0.829
Absolute Event Rate: 92.5% vs 85%
The Anysis-200 system demonstrates equivalent accuracy and significant agreement with VerifyNow for assessing aspirin responsiveness in cardiology patients.
No takes yet. Share an insight, caveat, or question.
Anysis-200 may support aspirin responsiveness testing as an alternative to VerifyNow; leaves open prospective outcome validation before clinical adoption.
Chung et al. (2020) conducted an observational in Cardiovascular disease (n=85). Anysis-200 vs. VerifyNow was evaluated on True positive rate in patients newly taking aspirin (AUC 0.829). The Anysis-200 platelet function analysis system showed high agreement with VerifyNow (Cohen's kappa 0.682), with 91.5% sensitivity and 75.5% specificity for aspirin responsiveness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: